In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs).

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities.

Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates (ADCs) in the management of advanced non-small cell lung cancer. Their engaging discussion will include topics such as HER2 biomarker testing, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated toxicities.

Visit https://suitehome.atpointofcare.com/library/2720.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thrombocythemia, and they review therapies on the horizon that are currently in late-stage clinical trials. What do clinicians need to know for managing this blood disorder?

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, Treatment Success in PV, Dr. Douglas Tremblay and Dr. Ruben Mesa focus on the goals of therapy for polycythemia vera, namely improving symptom burden and reducing thrombosis.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, From Clues to Classification, PV and ET Diagnosis Risk Stratification, Dr. Douglas Tremblay and Dr. Ruben Mesa discuss how clinicians can make an accurate diagnosis for these two blood disorders and how to prevent vascular complications, particularly how risk stratification can guide therapeutic shared decision-making.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, our faculty, Dr. Justin F. Gainor and Elizabeth A. Krueger, CNP, discuss practical and evidence-based strategies for managing patients with RET fusion-positive NSCLC. Learn about the defining pathologic features that distinguish this lung cancer, the recommended testing modalities for RET fusions, treatment selection, and how to manage adverse effects.

Visit https://suitehome.atpointofcare.com/library/2694.02/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including some of the latest clinical data from the anaplastic lymphoma kinase (ALK) trials, and real-world strategies to manage toxicities in patients with ALK-positive NSCLC.

Visit https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.